Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients
Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
TB is the most common cause of death in patients with HIV worldwide. Rifampicin [RIF] is the
cornerstone of anti-TB therapy. Current guideline recommend efavirenz (EFV) 600mg per day as
the first of choice for HIV/TB co-infection. Co-administration of EFV with RIF decrease the
plasma concentration of EFV. Because of better safety profiles, EFV 400mg has replaced the
EFV 600mg as the first-line antiretroviral therapy in people living with HIV. However, the
efficacy of EFV 400mg when co-administrated with RIF in HIV/TB co-infection is unclear. This
study is designed to evaluate the efficacy and safety of EFV 400mg versus EFV 600mg in HIV/TB
co-infected patients receiving RIF based anti-TB therapy.